CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2020; 80(11): 1093-1104
DOI: 10.1055/a-1124-7225
GebFra Science
Review/Übersicht

Liquid Biopsy in Breast Cancer

Article in several languages: English | deutsch
Maggie Banys-Paluchowski
1  Frauenklinik, Asklepios Klinik Barmbek, Hamburg, Germany
,
Natalia Krawczyk
2  Universitäts-Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
,
Tanja Fehm
2  Universitäts-Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
› Author Affiliations

Abstract

In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.



Publication History

Received: 29 June 2020

Accepted after revision: 02 August 2020

Publication Date:
06 November 2020 (online)

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany